Severe aplastic anemia (SAA) is a life-threatening, rare bone marrow failure disorder in which hematopoietic stem cell damage prevents adequate production of red blood cells, white blood cells, and platelets.
Allogeneic hematopoietic stem-cell transplantation (HSCT/BMT), including cord blood transplantation, remains the only curative therapy and is preferred when a suitable donor is available, particularly for younger and medically fit patients. When a matched donor cannot be identified, patients are typically treated with immunosuppressive therapy (IST) using horse antithymocyte globulin (ATG), cyclosporine, and eltrombopag, which improves survival but does not restore normal marrow function in all cases.
In a recent NIH-funded study, researchers reported a 94% survival rate with omidubicel—an ex vivo-expanded umbilical cord blood graft used in cord blood transplantation—in patients with SAA who lacked matched donors.
This finding is particularly significant for Black patients, who are far less likely to identify compatible bone marrow donors because transplant eligibility is largely determined by human leukocyte antigen (HLA) genetics rather than disease severity. Expanding donor-independent transplant options may improve outcomes for conditions that disproportionately affect Black patients, including sickle cell disease, marrow failure syndromes, and certain hematologic malignancies.
Traditional cord blood transplantation uses hematopoietic stem cells collected from the umbilical cord and placenta at birth, cryopreserved, and later infused intravenously to replace damaged bone marrow.
Cord blood offers immunological flexibility and a lower incidence of graft-versus-host disease (GVHD), but the low stem cell dose has limited its clinical use in adults. This leads to delayed neutrophil recovery, prolonged infection risk, graft failure, relapse, and extended hospitalization.
Omidubical is an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood. The expansion process increases CD34+ stem cell numbers before infusion, accelerating neutrophil engraftment and shortening the early post-transplant vulnerability period.
By overcoming the cell-dose limitation, omidubicel allows cord blood to function more like an adult donor graft while retaining its reduced matching requirements.
Potential clinical advantages include:
Umbilical cord blood has long been considered a preferred graft source because it requires less strict HLA matching. However, adult use has been limited by insufficient stem cell dose, resulting in delayed neutrophil recovery, infection risk, and graft failure.
Because of these risks, cord blood transplantation was typically reserved for patients with other options rather than used as a standard alternative donor strategy.
In the study, 94% of patients experienced rapid neutrophil engraftment, meaning that their white blood cell count recovered within an average of 8 days—substantially faster than in standard umbilical cord transplantation. By day 100, most patients demonstrated durable donor engraftment, signaling stable long-term hematopoiesis.
For clinicians, the importance of this outcome extends beyond overall survival. Faster neutrophil recovery shortens the period of profound immunosuppression that historically drives early transplant mortality in cord blood recipients. As a result, patients have a lower risk of severe infections and lower transplant-related mortality compared with expected outcomes for alternative donor transplants in SAA.
Rather than simply improving success rates, the findings alter the risk profile of cord blood transplantation. A graft source previously reserved for last-line use may now function as a viable frontline option when matched donors are unavailable.
“The results of this ongoing study are extremely encouraging and indicate a significant advancement in the treatment options for patients with a high unmet medical need. Patients in the study were high-risk but had significantly better than expected outcomes,” said Richard Childs, M.D., assistant U.S. Surgeon General, NIH study lead, and scientific director of NIH’s National Heart, Lung, and Blood Institute.
Historically, Black patients face lower access and higher mortality rates for stem cell transplantation. Allogeneic stem cell transplantation depends on close HLA matching, which is most likely to occur among individuals with shared ancestry. Because donor registries remain disproportionately composed of donors of European descent, Black patients are significantly less likely to identify compatible unrelated donors.
Because of this, transplant eligibility is often determined less by disease severity than by donor availability—a structural barrier that contributes to delayed treatment and poorer outcomes in marrow failure and hematologic malignancies for Black patients.
Traditional stem cell transplantation heavily depends on identifying a closely matched donor, a requirement that disproportionately limits access for patients of African descent. Cord blood offers a workaround by allowing less stringent HLA matching, but its clinical use in adults has been limited by low cell dose and delayed immune function recovery.
Expanded technology addresses this biological limitation, with omidubicel enabling faster engraftment in cord blood while preserving its reduced matching requirements.
For clinicians, this means transplant decisions may rely on a banked graft source instead of donor registry availability. In practice, eligibility can shift away from ancestry-linked matching probabilities toward clinical indications.
For Black patients and other populations underrepresented in donor registries, this represents a structural change in access.
While the study focused on severe aplastic anemia, the barrier addressed—donor availability—applies to multiple blood disorders.
Curative transplantation already exists for many of the diseases that disproportionately affect Black patients, including sickle cell disease, myelodysplastic syndromes, and certain leukemias. In many cases, the limiting factor is not the effectiveness of transplantation but the inability to locate a compatible donor in time.
If engraftment speed and safety profiles remain consistent across broader populations, expanded cord blood grafts could enable these patients to access established curative therapies earlier in the disease course.
The reported 94% survival rate represents more than just a successful trial on severe aplastic anemia—it suggests a potential shift in how transplant candidacy is determined.
Many patients have been excluded from curative transplantation due to donor incompatibility rather than disease biology. Cord blood expansion may allow clinicians to base transplant decisions more on medical need and less on ancestry-linked matching probability.
If this treatment approach is effective across additional hematologic malignancies, it could significantly narrow a longstanding treatment gap by transforming donor availability from a limiting factor into a logical step.
By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.
Are you a healthcare professional? Register with us today!